NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Braveheart Bio, Inc. (BRVE) Stock Analysis

Braveheart Bio, Inc. (BRVE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BRVE

$21.04

+$0.77 (+3.80%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BRVE with… →

BRVE Key Statistics

As of Oct 21, 2026
Trading
Open
$20.64
Previous Close
$20.27
Day's Range
19.67–21.31
52-Week Range
17.86–32.00
Volume
224.15K
Valuation
Market Cap
$1.74B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−6.08
Financials (FY)
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
90.04M
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
543.35K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Braveheart Bio, Inc. (BRVE) has a market capitalization of $1.74B.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Braveheart Bio, Inc. (BRVE) at $1.74B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 49 employees.

BRVE last closed at $21.04 on October 21, 2026. That is +$0.77 (+3.80%) against the previous close. The 52-week range on file runs from $17.86 to $32.00. The latest close sits 17.81% above that 52-week low.

Financial Health

Earnings per share on a trailing basis come to −6.08.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

The record shows no dividend for BRVE.

2026 is still running; the total return is −29.40% year to date.

Peer Comparison

Braveheart Bio, Inc. (BRVE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Braveheart Bio, Inc. BRVE $1.74B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Braveheart Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Braveheart Bio, Inc.

Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.

Visit website →